Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Clinical trial NCT03675737 · COMPLETED
Trial details
- NCT number
- NCT03675737
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-08
- Primary completion
- 2022-10-03
- Enrollment
- 1579
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.